Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BetterLife Pharma Inc. (C:BETR)

Business Focus: Bio Therapeutic Drugs

Jan 02, 2024 08:00 am ET
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the...
Dec 18, 2023 08:00 am ET
BetterLife Announces Closing of a Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Nov 30, 2023 08:00 am ET
BetterLife Announces Extension of Warrants
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announces that, effective...
Nov 15, 2023 08:00 am ET
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Sep 14, 2023 08:00 am ET
BetterLife Pharma to Host Investors Update Call on September 18, 2023
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that...
Sep 12, 2023 08:00 am ET
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it...
Sep 05, 2023 08:00 am ET
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Jul 13, 2023 08:00 am ET
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to highlight the...
Jun 27, 2023 08:00 am ET
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced the fast...
Jun 22, 2023 08:00 am ET
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its...
Jun 08, 2023 08:00 am ET
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the...
Apr 25, 2023 08:00 am ET
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its...
Apr 24, 2023 08:00 am ET
BetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - BetterLife Pharma (CSE: BETR), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.
Apr 20, 2023 08:00 am ET
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Mar 29, 2023 08:00 am ET
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce...
Mar 22, 2023 08:00 am ET
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce...
Mar 14, 2023 01:21 pm ET
CORRECTION -- BetterLife Closes $1,857,143 of Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) announces a correction to its press release entitled “BetterLife Closes $1,857,143 of Private Placement” issued today (the “Initial Press Release”). The...
Mar 14, 2023 10:00 am ET
BetterLife Closes $1,857,143 of Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the...
Mar 10, 2023 07:10 pm ET
BetterLife Files Amended and Restated Offering Document for Offering of Units
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announces that it has...
Mar 09, 2023 08:00 am ET
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Mar 08, 2023 12:30 pm ET
BetterLife Announces Pricing of Proposed Offering of Units
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce...
Mar 08, 2023 11:39 am ET
IIROC Trade Resumption - BETR
VANCOUVER, BC, March 8, 2023 /CNW/ - Trading resumes in:
Mar 08, 2023 08:44 am ET
IIROC Trading Halt - BETR
VANCOUVER, BC, March 8, 2023 /CNW/ - The following issues have been halted by IIROC:
Mar 07, 2023 04:01 pm ET
BetterLife Announces Offering of Units
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce a...
Jan 26, 2023 08:00 am ET
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the...
Dec 07, 2022 08:00 am ET
BetterLife Announces Closing of Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) is pleased to announce that it has closed a non-brokered private placement (the "Offering") by issuing 3,160,000 common shares at a price of USD$0.15 per...
Dec 02, 2022 08:00 am ET
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that one of...
Sep 27, 2022 08:00 am ET
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce...
Sep 07, 2022 08:00 am ET
BetterLife and Collaborators to Submit Key Joint Research Publication
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Aug 24, 2022 08:00 am ET
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders. A recent study,...
Jul 06, 2022 08:00 am ET
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Jun 23, 2022 08:00 am ET
BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr....
Jun 21, 2022 08:00 am ET
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an...
Apr 21, 2022 08:00 am ET
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an...
Apr 06, 2022 08:00 am ET
BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it...
Mar 16, 2022 08:00 am ET
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of second generation non-hallucinogenic psychedelic analogs for the...
Feb 15, 2022 08:00 am ET
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs for the treatment...
Feb 10, 2022 08:00 am ET
BetterLife Launches New Corporate Website
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR/ OTCQB: BETRF/ FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of...
Jan 20, 2022 08:00 am ET
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment...
Jan 18, 2022 08:00 am ET
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment...
Jan 06, 2022 08:00 am ET
Dr. Eleanor Fish, Advisory Board Member, Awarded Order of Canada
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is extremely pleased to...
Dec 22, 2021 10:30 am ET
BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), has signed an agreement with an European-based investor group to...
Dec 22, 2021 09:57 am ET
IIROC Trade Resumption - BETR
VANCOUVER, BC, Dec. 22, 2021 /CNW/ - Trading resumes in:
Dec 22, 2021 07:24 am ET
IIROC Trading Halt - BETR
VANCOUVER, BC, Dec. 22, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 09, 2021 08:00 am ET
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it...
Dec 03, 2021 08:00 am ET
H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Nov 29, 2021 08:00 am ET
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have successfully...
Nov 16, 2021 08:00 am ET
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it...
Nov 05, 2021 08:00 am ET
Developing Psychedelic Medicine Beyond What We Already Know!
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will participate in a panel...
Nov 04, 2021 08:00 am ET
BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Oct 25, 2021 08:00 am ET
BetterLife Pharma: Invitation to the Benzinga Global Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - October 25, 2021) - BetterLife Pharma (CSE: BETR) will be presenting at the Benzinga Global Small Cap Conference taking place on October 27-28, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Oct 12, 2021 08:00 am ET
Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU ), an emerging biotech company focused on the development and commercialization of inhaled antiviral therapy against COVID-19 and emerging viral infections,...
Oct 11, 2021 09:25 am ET
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 
Sep 29, 2021 08:00 am ET
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Sep 27, 2021 08:00 am ET
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it...
Sep 22, 2021 08:00 am ET
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have enrolled the...
Sep 13, 2021 08:00 am ET
BetterLife to Present at the Emerging Growth Conference on September 15, 2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce that it has been...
Sep 09, 2021 08:00 am ET
BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces an agreement with Laboratory of...
Aug 25, 2021 08:00 am ET
BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce initiation of in...
Jul 27, 2021 08:00 am ET
BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have obtained...
Jul 22, 2021 08:00 am ET
BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application...
Jul 19, 2021 08:00 am ET
BetterLife to Present at the Emerging Growth Conference
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU ), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce that it has been...
Jul 15, 2021 08:00 am ET
Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce early positive in...
Jul 12, 2021 08:00 am ET
BetterLife Provides H1 2021 Progress Update
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces significant progress in H1 2021....
Jun 25, 2021 09:50 am ET
BetterLife Announces Exercise of Over-Allotment Option in Public Offering
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ), is pleased to announce the partial exercise of the over-allotment option in conjunction with the Company’s $2,610,000 marketed public offering (the...
Jun 24, 2021 08:00 am ET
BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is...
Jun 22, 2021 08:00 am ET
BetterLife Pharma Engages Global Financial and Corporate Communications Agency
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has engaged U.K.-based financial and corporate communications consultancy Buchanan...
Jun 15, 2021 08:00 am ET
BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU), an emerging biotech company focused on non-hallucinogenic psychedelic therapeutics, today announced that Ahmad Doroudian, Chief Executive Officer, will be...
Jun 10, 2021 08:00 am ET
BetterLife Pharma Retains Proactive Investors and Psychedelic Finance for Market Awareness
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has retained Proactive Investors (“Proactive”) and Psychedelic Finance to broaden the...
Jun 07, 2021 10:31 am ET
BetterLife Closes $2.61 Million Marketed Public Offering
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce the closing of its marketed public offering pursuant to which the Company issued 6,525,000 units of the Company (the “Units”) at a...
Jun 02, 2021 08:00 am ET
BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of...
May 31, 2021 04:17 pm ET
BetterLife Announces Marketed Public Offering of Units for up to $2.6 Million
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ), is pleased to announce that it has entered into an agreement with Research Capital Corporation as sole agent and sole bookrunner (the “Agent”) in...
May 28, 2021 09:49 am ET
BetterLife Closes $6.325 Million Bought Deal Public Offering of Units, Including Full Exercise of the Over-Allotment Option
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ) is pleased to announce the closing of its bought-deal public offering pursuant to which the Company issued 15,812,500 units of the Company (the “Units”)...
May 20, 2021 07:26 pm ET
BetterLife Announces $5.5 Million Bought-Deal Public Offering of Units
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ), is pleased to announce that it has entered into an agreement with Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf...
May 14, 2021 08:00 am ET
BetterLife Announces Closing of a Non-Brokered Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) is pleased to announce that it has closed a non-brokered private placement (the "Offering") with one strategic investor by issuing 1,142,857 common...
Apr 29, 2021 08:00 am ET
BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that...
Apr 28, 2021 09:00 am ET
April Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass Adoption
Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund, the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital.
Apr 08, 2021 08:00 am ET
Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotechnology company developing second generation psychedelics for neuro-psychiatric disorders, today announced that Dr. Thomas...
Mar 29, 2021 08:00 am ET
BetterLife Added to Horizons Psychedelic Stock Index ETF
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU) is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF (PSYK : NEO), the world's first ETF offering direct exposure to...
Mar 24, 2021 07:45 am ET
BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
VANCOUVER, BC / ACCESSWIRE / March 24, 2021 / BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE:BETR) / (OTCQB:BETRF) / (FRA:NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announces an agreement with the laboratory of Dr. Adam L. Halberstadt at the University of California San Diego ("UCSD") for TD-0148A preclinical behavioural phar
Mar 11, 2021 08:00 am ET
BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), today announced that its wholly-owned subsidiary, Altum Pharmaceuticals (“Altum”) has entered into a Letter of Intent with Pontificia Universidad...
Mar 08, 2021 08:00 am ET
BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections,...
Mar 03, 2021 08:00 am ET
BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders and viral infections,...
Feb 16, 2021 07:00 am ET
BetterLife to Present at the Emerging Growth Conference on February 17, 2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has been invited to present at the Emerging Growth Conference on February 17, 2021. The...
Feb 02, 2021 08:30 am ET
BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections,...
Jan 28, 2021 02:00 am ET
BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections,...
Jan 26, 2021 08:30 am ET
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, today...
Jan 21, 2021 08:30 am ET
BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to...
Jan 19, 2021 02:00 am ET
BetterLife Confirms Non-controlled Status of 2-bromo-LSD with Health Canada
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is...
Jan 12, 2021 02:00 am ET
BetterLife Provides Shareholder Update and 2021 Product Development Roadmap
VANCOUVER, January 12, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and...
Jan 07, 2021 09:00 am ET
BetterLife Announces Formation of Next Generation Psychedelic Research Advisory Board
January 7, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce the formation of its Next Generation Psychedelic Research Advisory Board and...
Jan 04, 2021 09:31 am ET
BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD
January 4, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce it has applied for patent protection of new 2-Bromo-LSD (“TD-0148A”) formulations...
Dec 29, 2020 02:00 am ET
BetterLife Pharma Strengthens Board of Directors
BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in...
Dec 23, 2020 02:00 am ET
BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team
BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined...
Dec 21, 2020 02:00 am ET
BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) is pleased to announce that further to its press release of December 8, 2020, the Company has completed its acquisition to acquire 100% of the assets in...
Dec 15, 2020 02:00 am ET
BetterLife’s Recent Acquisition: Taking LSD from Experimental to a Major Therapeutic Application
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting edge treatments, today announced the value proposition of its acquisition...
Dec 08, 2020 08:55 am ET
BetterLife adds Next-Gen Psychedelic Therapy to its Pipeline of Drugs
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech focused on the development and commercialization of revolutionary treatments, today announced the signing of a definitive agreement to...
Dec 08, 2020 08:14 am ET
IIROC Trade Resumption - BETR
VANCOUVER, BC, Dec. 8, 2020 /CNW/ - Trading resumes in:
Dec 07, 2020 01:37 pm ET
IIROC Trading Halt - BETR
VANCOUVER, BC, Dec. 7, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 02, 2020 01:33 pm ET
BETTERLIFE PHARMA ANNOUNCES CLOSING OF $2.9 MILLION PRIVATE PLACEMENT OFFERING
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT), an emerging biotech company, is pleased to announce that it has closed its previously announced private placement offering of special warrants of the...
Nov 18, 2020 07:30 am ET
What do the Pfizer Vaccine and BetterLife Pharma have in common?
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and commercialization of interferon (IFN) based therapeutics, recently provided a clinical and...
Nov 10, 2020 07:30 am ET
Pre-IND Discussion with U.S. FDA Helps BetterLife Set Up AP-003 Clinical Trials in Australia
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company focused on development and commercialization of interferon based treatments, today announced a clinical and regulatory update...
Nov 04, 2020 08:00 am ET
BetterLife Pharma Signs eTMF Partner to Help Accelerate AP-003 Clinical Trial Operations
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company that is beginning clinical trials of AP-003, its COVID-19 inhalation therapeutic, announced today that it has selected...
Oct 28, 2020 08:00 am ET
BetterLife Provides Important Update on its Australian Clinical Study Design
BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, today provided the following update regarding how it...
Oct 28, 2020 05:00 am ET
UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta
UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company...
Oct 27, 2020 07:30 am ET
BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Other Treatements
The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, its interferon alpha 2b COVID-19 treatment, joined investor portal Proactive to...
Oct 19, 2020 08:00 am ET
BETTERLIFE PHARMA ANNOUNCES UP TO $5.0 MILLION PRIVATE PLACEMENT OFFERING OF SPECIAL WARRANTS
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE:...
Oct 15, 2020 08:00 am ET
BetterLife Names CRO for COVID-19 Clinical Trial in Australia
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, is pleased to announce that it has engaged the Clinical Research Organisation (“CRO”) Pharmaceutical Solutions Ltd. to manage...
Oct 08, 2020 08:00 am ET
BetterLife Announces VirTrial as Clinical Trial Patient Monitoring Partner
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, is pleased to announce that it will be teaming up with VirTrial, LLC (“VirTrial”) to conduct patient monitoring for their...
Sep 30, 2020 07:30 am ET
BetterLife Receives FINRA Approval and Resumes Trading on the OTC Markets
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, is pleased to announce that, further to its news release of September 23, 2020, Glendale Securities, Inc. (who acted as the...
Sep 23, 2020 07:30 am ET
BetterLife Provides Update on OTC Trading Activity
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that it has filed a Form 211 application with the Financial Industry Regulatory Authority (“FINRA”) to...
Sep 17, 2020 07:30 am ET
BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of...
Sep 09, 2020 07:30 am ET
BetterLife CEO Interview on Canadian Stock Exchange Podcast Discussing Recent Advancements Now Live
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that Company CEO Dr. Ahmad Doroudian was interviewed by the Canadian Stock Exchange (CSE) to discuss...
Sep 08, 2020 07:30 am ET
BetterLife Pharma Engages Hybrid Financial Ltd.
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to...
Sep 02, 2020 07:30 am ET
BetterLife Pharma Announces Dr. Eleanor Fish to Retain Role as Key Scientific Advisor Following Invitation to Join Government COVID-19 Task Force
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company, today announced that Dr. Eleanor Fish will continue to play a key role as part of the Company's Scientific Advisory...
Sep 01, 2020 09:32 am ET
IIROC Trade Resumption - BETR
VANCOUVER, BC, Sept. 1, 2020 /CNW/ - Trading resumes in:
Sep 01, 2020 07:30 am ET
BetterLife Resumes Trading Following CSE Merger Ratification with Altum Pharmaceuticals
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce  that it has received confirmation from the Canadian Stock Exchange (the "Exchange") that its common shares will resume trading...
Aug 31, 2020 03:54 pm ET
CSE Bulletin: Fundamental Change - BetterLife Pharma Inc. (BETR)
Toronto, Ontario--(Newsfile Corp. - Le 31 aout/August 2020) - Following a fundamental change review the common shares of BetterLife Pharma Inc. have requalified for listing.
Aug 11, 2020 07:00 am ET
BetterLife Announces Closing of Private Placement
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has closed the first tranche of its non-brokered private placement (the "Offering") by issuing 716,725 units ("Units") at a...
Aug 05, 2020 07:30 am ET
BetterLife Announces Trading Halt Following Merger with Altum
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company, announced that trading of its ordinary shares on the Canadian Stock Exchange (“CSE”) and OTC Markets (United States)...
Jul 31, 2020 01:38 pm ET
IIROC Trading Halt - BETR
VANCOUVER, BC, July 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 30, 2020 07:30 am ET
BetterLife Pharma Receives Approval from Altum Pharmaceuticals Inc. Shareholders to Complete Merger
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company with proprietary interferon-based therapeutic technologies, is pleased to provide an update on the results of the...
Jul 28, 2020 08:00 am ET
BetterLife CEO Discusses Synairgen’s Interferon Breakthrough Treatment
The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing a potential coronavirus treatment for clinical trials, recently joined investor portal Proactive to discuss the...
Jul 27, 2020 04:00 am ET
BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan
VANCOUVER, BC, July 27, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to provide an update on the proposed acquisition of Altum Pharmaceuticals Inc. ("Altum") and its upcoming clinical programs.  A Special Meeting of Altum shareholders, more than 72% of whom have signed a Lock Up Agreement, is scheduled for July 29th 2020 to approve the merger with BetterLife. The results of the vote will be announced shortly thereafter.
Jul 27, 2020 04:00 am ET
BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan
VANCOUVER, BC, July 27, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to provide an update on the proposed acquisition of Altum Pharmaceuticals Inc. ("Altum") and its upcoming clinical programs.  A Special Meeting of Altum shareholders, more than 72% of whom have signed a Lock Up Agreement, is scheduled for July 29th 2020 to approve the merger with BetterLife. The results of the vote will be announced shortly thereafter.
Jul 24, 2020 04:30 pm ET
BetterLife Pharma Issues Update on its Promotional Activity
BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRF / CSE:  BETR / FRA: NPAT) provides the following information about certain promotional activities at the request of OTC Markets.Recently, BetterLife has proactively engaged a...
Jul 23, 2020 08:00 am ET
BetterLife CEO Discusses Merger, Planned Interferon Treatment Trials and Potential Subsequent FDA Emergency Use Authorization
The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own interferon-based coronavirus treatment clinical trials, recently joined online portal Proactive for a Q&A...
Jul 21, 2020 08:00 am ET
Interferon Treatment Trial 'a Major Breakthrough' Against the Pandemic
BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRD) (CSE:BETR) has been a strong advocate and defender of using interferons as treatment for COVID-19, in particular as delivered through an inhalation device. Now, the preliminary...
Jul 14, 2020 08:00 am ET
BetterLife (OTCQB:BETRD) Launches Website Emphasizing 3 Potentially Ground Breaking Treatments
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE:BETR) (OTCQB:BETRD) (FRA: BLife Therapeutics BLife TherapeuticsNPAT) indicated the finalisation of its rebranding exercise for its wholly owned subsidiary, BLife Therapeutics, which has...
Jul 06, 2020 07:30 am ET
BetterLife Pharma (OTCB:BETRD) CEO Discusses Using Interferons to Defeat ‘Truly Evil Virus’
The CEO of BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, recently discussed the use of interferon therapy for COVID-19 with Alex Keown of BioSpace. Highlights of the...
Jun 30, 2020 12:55 pm ET
BetterLife Pharma (OTCQB:BETRD) Believe Inhalation Device Containing Proprietary Interferon May Fight Off COVID-19
BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, believe that a coronavirus inhaler therapeutic may hold the key to helping patients fight off symptoms of coronavirus as...
Jun 25, 2020 08:00 pm ET
BetterLife Pharma Announces Consolidation of its Common Shares
VANCOUVER, BC, June 25, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) announces that it has consolidated its common shares on the basis of one new common share for ten old common shares (the "Consolidation").   
Jun 25, 2020 08:00 pm ET
BetterLife Pharma Announces Consolidation of its Common Shares
VANCOUVER, BC, June 25, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) announces that it has consolidated its common shares on the basis of one new common share for ten old common shares (the "Consolidation").   
Jun 23, 2020 03:18 pm ET
CSE Bulletin: Consolidation - BetterLife Pharma Inc. (BETR)
Toronto, Ontario--(Newsfile Corp. - June 23, 2020) - BetterLife Pharma Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common shares for ten (10) pre-consolidation common shares.
Jun 19, 2020 07:57 am ET
BetterLife Pharma (OTCQB:BETRF) Looks to Immune Response Drug Interferon a2b as Potential Therapeutic for COVID-19
BetterLife Pharma (OTCQB:BETRF) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, announced recently that it is exploring the potential of using a patent-pending proprietary interferon a2b (IFN a2b)...
Jun 11, 2020 06:00 am ET
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
VANCOUVER, BC, June 11, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to announce that it has entered into an exclusivity agreement with Altum Pharmaceuticals Inc. ("Altum") to work towards finalizing a mutually acceptable definitive agreement for the "merger of equals" transaction, pursuant to which BetterLife would issue 4.582 common shares of BetterLife for each Altum common share, which represented approximately $36.1 million in value based on the proposed share exchange as at May 25, 2020.
Jun 11, 2020 06:00 am ET
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
VANCOUVER, BC, June 11, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to announce that it has entered into an exclusivity agreement with Altum Pharmaceuticals Inc. ("Altum") to work towards finalizing a mutually acceptable definitive agreement for the "merger of equals" transaction, pursuant to which BetterLife would issue 4.582 common shares of BetterLife for each Altum common share, which represented approximately $36.1 million in value based on the proposed share exchange as at May 25, 2020.
Jun 09, 2020 06:00 am ET
BetterLife Pharma Announces OTC Trading Symbol Change to "BETRF" Effective June 9, 2020
VANCOUVER, BC, June 9, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to announce that the Financial Industry Regulatory Authority, Inc. ("FINRA") has approved the Company's request to change its OTC ticker symbol from PVOTF to BETRF, effective as of the opening of market trading on June 9, 2020.
Jun 09, 2020 06:00 am ET
BetterLife Pharma Announces OTC Trading Symbol Change to "BETRF" Effective June 9, 2020
VANCOUVER, BC, June 9, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to announce that the Financial Industry Regulatory Authority, Inc. ("FINRA") has approved the Company's request to change its OTC ticker symbol from PVOTF to BETRF, effective as of the opening of market trading on June 9, 2020.
Jun 04, 2020 06:00 am ET
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
VANCOUVER, BC, June 4, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: PVOTF) (FSE: NPAT) is pleased to provide an update to its press release of May 25, 2020 whereby BetterLife announced that it secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals Inc. ("Altum") representing 67.12% of the outstanding common shares of Altum. BetterLife obtained these lock-up agreements as it had reason to believe that the independent members of the Board of Altum were attempting to cancel the licensing agreement between BetterLife and Altum purs
Jun 04, 2020 06:00 am ET
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
VANCOUVER, BC, June 4, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: PVOTF) (FSE: NPAT) is pleased to provide an update to its press release of May 25, 2020 whereby BetterLife announced that it secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals Inc. ("Altum") representing 67.12% of the outstanding common shares of Altum. BetterLife obtained these lock-up agreements as it had reason to believe that the independent members of the Board of Altum were attempting to cancel the licensing agreement between BetterLife and Alt
May 25, 2020 12:10 pm ET
IIROC Trade Resumption - BETR
VANCOUVER, May 25, 2020 /CNW/ - Trading resumes in:
May 25, 2020 11:44 am ET
BetterLife Pharma Secures Lock-Up Agreements From Shareholders of Altum
VANCOUVER, May 25, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) is pleased to announce that it has, as of the date hereof, secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals Inc. ("Altum") representing 67.12% of the outstanding common shares of Altum.
May 25, 2020 11:44 am ET
BetterLife Pharma Secures Lock-Up Agreements From Shareholders of Altum
VANCOUVER, May 25, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) is pleased to announce that it has, as of the date hereof, secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals Inc. ("Altum") representing 67.12% of the outstanding common shares of Altum.
May 25, 2020 08:19 am ET
IIROC Trading Halt - BETR
VANCOUVER, May 25, 2020 /CNW/ - The following issues have been halted by IIROC:
May 19, 2020 06:00 am ET
BetterLife Pharma Announces Appointment of Dr. Eleanor Fish, a leading expert on interferon activity against Covid-19, to its Advisory Board
VANCOUVER, May 19, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Eleanor Fish to the Company's Scientific Advisory Board. Dr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zika.
May 19, 2020 06:00 am ET
BetterLife Pharma Announces Appointment of Dr. Eleanor Fish, a leading expert on interferon activity against Covid-19, to its Advisory Board
VANCOUVER, May 19, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Eleanor Fish to the Company's Scientific Advisory Board. Dr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zika.
May 15, 2020 02:00 pm ET
BetterLife Pharma announces release of exploratory study on treatment of Covid-19 patients in Wuhan with Interferon
VANCOUVER, May 15, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the journal Frontiers of Immunology ("Frontiers") released the results of the exploratory study on Treatment on a cohort of confirmed COVID-19 cases in Wuhan. The study can be found at https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full and an article summarizing the results of the study can be found at https://medicalxpress.com/news/2020-05-treatment-interferon-2b-recovery-covid-patients.html
May 15, 2020 02:00 pm ET
BetterLife Pharma announces release of exploratory study on treatment of Covid-19 patients in Wuhan with Interferon
VANCOUVER, May 15, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the journal Frontiers of Immunology ("Frontiers") released the results of the exploratory study on Treatment on a cohort of confirmed COVID-19 cases in Wuhan. The study can be found at https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full and an article summarizing the results of the study can be found at https://medicalxpress.com/news/2020-05-treatment-interferon-2b-recovery-covid-patients.html
May 13, 2020 12:21 pm ET
BetterLife Pharma announces Interferon Alpha-2b Covid-19 news regarding its emergence as a potential treatment for COVID-19
VANCOUVER, May 13, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that a third party study is scheduled to be released this Friday in the journal Frontiers of Immunology. The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that the interferon alpha-2b drug significantly accelerated clearance of the virus from the airways of patients.
May 13, 2020 12:21 pm ET
BetterLife Pharma announces Interferon Alpha-2b Covid-19 news regarding its emergence as a potential treatment for COVID-19
VANCOUVER, May 13, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that a third party study is scheduled to be released this Friday in the journal Frontiers of Immunology. The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that the interferon alpha-2b drug significantly accelerated clearance of the virus from the airways of patients.
May 12, 2020 09:17 am ET
BetterLife Pharma Confirms Re-Pricing of Warrants
VANCOUVER, May 12, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) confirms the re-pricing of warrants issued pursuant to financings completed in 2019 as announced in the Company's press release dated May 7, 2020. 
May 12, 2020 09:17 am ET
BetterLife Pharma Confirms Re-Pricing of Warrants
VANCOUVER, May 12, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) confirms the re-pricing of warrants issued pursuant to financings completed in 2019 as announced in the Company's press release dated May 7, 2020. 
May 11, 2020 09:19 am ET
BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon and Announces Appointment of Dr. Mark Swaim and Engagement of IR Group
VANCOUVER, May 11, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Mark Swaim to the board of directors of its wholly-owned subsidiary, Blife Therapeutics Inc. The Company also highlights the results of the use of Interferon against Covid-19 in recent clinical observations and experiments.
May 11, 2020 09:19 am ET
BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon and Announces Appointment of Dr. Mark Swaim and Engagement of IR Group
VANCOUVER, May 11, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Mark Swaim to the board of directors of its wholly-owned subsidiary, Blife Therapeutics Inc. The Company also highlights the results of the use of Interferon against Covid-19 in recent clinical observations and experiments.
May 07, 2020 12:14 pm ET
IIROC Trade Resumption - BETR
VANCOUVER, May 7, 2020 /CNW/ - Trading resumes in:
May 07, 2020 12:02 pm ET
BetterLife Pharma Enters into a Licensing Agreement
VANCOUVER, May 7, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has entered into an agreement to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a potential COVID-19 treatment, from Altum Pharmaceuticals Inc. ("Altum"). AntiCovir is an Interferon a2b ("IFNa2b ") based potential treatment that is proposed to be administered using a Metered Dose Inhaler ("MDI") or a nebulizer. Altum is currently preparing protocol and application to conduct
May 07, 2020 12:02 pm ET
BetterLife Pharma Enters into a Licensing Agreement
VANCOUVER, May 7, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has entered into an agreement to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a potential COVID-19 treatment, from Altum Pharmaceuticals Inc. ("Altum"). AntiCovir is an Interferon a2b ("IFNa2b ") based potential treatment that is proposed to be administered using a Metered Dose Inhaler ("MDI") or a nebulizer. Altum is currently preparing protocol and application to
May 07, 2020 08:28 am ET
IIROC Trading Halt - BETR
VANCOUVER, May 7, 2020 /CNW/ - The following issues have been halted by IIROC:
Apr 07, 2020 09:00 am ET
BetterLife Pharma Provides Shareholder Update
VANCOUVER, April 7, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the launch of its branded products is on target for the second and third quarter despite of the disruption to the global supply chain. 
Apr 07, 2020 09:00 am ET
BetterLife Pharma Provides Shareholder Update
VANCOUVER, April 7, 2020 /PRNewswire/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the launch of its branded products is on target for the second and third quarter despite of the disruption to the global supply chain. 
Feb 03, 2020 07:59 am ET
BetterLife Pharma Acquires Swiss Based Solmic AG with Unique Global Patent for Production of New Generation CBD based Biopharmaceuticals
VANCOUVER, Feb. 3, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced the acquisition of Swiss based Solmic AG with its strong IP portfolio including unique formulation technology for the production of stable micelles containing water insoluble compounds such as CBD. Solmic AG's unique micelle production technology has been shown to greatly enhance the bioavailability of fat soluble ingredients by as much as 15 times. This technology allows for accelerated uptake of cannabinoids in the human digestive tract. A unique Sol
Jan 22, 2020 05:00 am ET
BetterLife Pharma strengthens Board of Directors and Management
The Company prepares for its upcoming launch of its branded product line in the US
Jan 06, 2020 05:00 am ET
BetterLife Pharma files site evidence package with Health Canada
VANCOUVER, Jan. 6, 2020 /CNW/ - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has submitted its site evidence package to Health Canada for the Company's cannabis formulation, processing and packaging facility in Montreal. The site evidence package submission is the final step required to obtain a license to produce CBD, phytocannabinoid and our advanced nutraceutical formulations at its state of the art facility.
Dec 05, 2019 05:00 am ET
Pivot Pharmaceuticals re-brands as BetterLife Pharma Inc
VANCOUVER, Dec. 5, 2019 /CNW/ - Pivot Pharmaceuticals Inc. today announced its corporate name change to BetterLife Pharma Inc. The Company will change its ticker symbol to BETR. taking effect immediately. BetterLife is committed to becoming a brand leader with its superior, proprietary phytocannabinoid and micronutrient product portfolio.